“We are excited by the inherent transformational potential of our exosome technology, which significantly improves and enables the delivery of a wide range of therapeutic molecules, including antibodies, proteins, nucleic acids and small molecules. Oxford-based Evox Therapeutics is poised to carry out phase 1 clinical trials of some of its rare disease candidates, after raising £35m ($45.4m) in series B funding from investors including Redmile Group and GV. The company has already completed a Phase 2 trial on the treatment for an inherited form of muscular dystrophy (MD) that was first discovered by Dr David Sinclair at Oxford University nearly 30 years ago.
Oxford-based Evox Therapeutics is poised to carry out phase 1 clinical trials of some of its rare disease candidates, after raising £35m ($45.4m) in series B funding from investors including Redmile Group and GV. The company has already completed a Phase 2 trial on the treatment for an inherited form of muscular dystrophy (MD) that was first discovered by Dr David Sinclair at Oxford University nearly 30 years ago.